Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hofseth BioCare ASAHOFBF 51 Cyclically Adjusted PS Ratio is 3.33 as of Jul. 21, 2026, which is 52% below its 10-year median of 7.00. GuruFocus rates HOFBF with a GF Score™ of 51/100 and a GF Value™ of $0.26. The stock has 6 warning signs investors should review. Among 1,448 Consumer Packaged Goods companies, Hofseth BioCare ASA ranks worse than 88.6% on this metric.
The historical rank and industry rank for Hofseth BioCare ASA's Cyclically Adjusted PS Ratio or its related term are showing as below:
HOFBF'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.73 Med: 7 Max: 26.49
Current: 3.36
During the past years, Hofseth BioCare ASA's highest Cyclically Adjusted PS Ratio was 26.49. The lowest was 2.73. And the median was 7.00.
HOFBF's Cyclically Adjusted PS Ratio is ranked worse than 88.6% of 1448
companies
in the Consumer Packaged Goods industry
Industry Median: 0.765
vs HOFBF: 3.36
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Hofseth BioCare ASA's adjusted revenue per share data for the three months ended in Mar. 2026 was $0.012. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.05 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Hofseth BioCare ASA (OTCPK:HOFBF) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Hofseth BioCare ASA Cyclically Adjusted PS Ratio Related Terms
Hofseth BioCare ASA Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Hofseth BioCare ASA's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hofseth BioCare ASA Cyclically Adjusted PS Ratio Chart
HOFBF vs KHC, GIS, HRL: Cyclically Adjusted PS Ratio Comparison
For the Packaged Foods subindustry, Hofseth BioCare ASA's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hofseth BioCare ASA Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Hofseth BioCare ASA's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Hofseth BioCare ASA's Cyclically Adjusted PS Ratio falls into.
Hofseth BioCare ASA Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Hofseth BioCare ASA's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 3.33 mean?
Hofseth BioCare ASA (HOFBF) has a Cyclically Adjusted PS Ratio of 3.33 as of Jul. 21, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hofseth BioCare ASA and its competitors. This is 52% below median its historical median of 7.00. Over the past decade, Hofseth BioCare ASA's Cyclically Adjusted PS Ratio has ranged from 2.73 to 26.49. According to the industry distribution chart, Hofseth BioCare ASA ranks #1283 out of 1448 companies in the Consumer Packaged Goods industry, placing it in the top 88.6%.
Is Hofseth BioCare ASA's Cyclically Adjusted PS Ratio too high?
Hofseth BioCare ASA's current Cyclically Adjusted PS Ratio of 3.33 is 52% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 2.73 to a high of 26.49. The Consumer Packaged Goods industry median Cyclically Adjusted PS Ratio is 0.77. Hofseth BioCare ASA's value of 3.33 is 335.3% above this industry median. Based on the distribution chart, Hofseth BioCare ASA ranks #1283 out of 1448 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Hofseth BioCare ASA has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Hofseth BioCare ASA's Cyclically Adjusted PS Ratio compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Hofseth BioCare ASA ranks #1283 out of 1448 companies for Cyclically Adjusted PS Ratio. This places Hofseth BioCare ASA in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 0.77. Hofseth BioCare ASA's value of 3.33 is 335.3% above this benchmark. Historically, Hofseth BioCare ASA's own Cyclically Adjusted PS Ratio has ranged from 2.73 to 26.49 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 0.77, Hofseth BioCare ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Consumer Packaged Goods company?
The median Cyclically Adjusted PS Ratio among Consumer Packaged Goods companies is 0.77, based on 1,448 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hofseth BioCare ASA's current Cyclically Adjusted PS Ratio of 3.33 is 335.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hofseth BioCare ASA and its competitors. For the Consumer Packaged Goods industry, the median Cyclically Adjusted PS Ratio is 0.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hofseth BioCare ASA's current Cyclically Adjusted PS Ratio is 3.33, which is 52% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hofseth BioCare ASA stock overvalued right now?
Hofseth BioCare ASA (HOFBF) has a current Cyclically Adjusted PS Ratio of 3.33. The stock's GF Value™ is $0.26, compared to a current price of $0.17 — trading 35.9% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 3.33, which is 52% below median its 10-year median of 7.00 and 335.3% above the Consumer Packaged Goods industry median of 0.77. Hofseth BioCare ASA's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Hofseth BioCare ASA (HOFBF), the current Cyclically Adjusted PS Ratio is 3.33 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hofseth BioCare ASA (HOFBF) Overvalued in 2026?
Based on GuruFocus' analysis, Hofseth BioCare ASA stock appears to be undervalued.
The current stock price of $0.17 is trading 35.9% below its estimated GF Value™ of $0.26.
Key valuation signals for HOFBF:
Cyclically Adjusted PS Ratio: 3.33 (52% below median its 10-year median of 7.00)
GF Value™: $0.26 vs. price of $0.17 (35.9% below fair value)
Industry Position: 335.3% above the Consumer Packaged Goods median (#1283 of 1448)
No single metric tells the full story. See the HOFBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hofseth BioCare ASA is a Norway-based company engaged in the business of developing, manufacturing, marketing, and selling marine ingredients such as oil, calcium, and protein products. Its brands, which also generate revenue, include salmon oil (OmeGo), water-soluble protein (ProGo), calcium/collagen (CalGo and NT-II), and non-soluble protein (PetGo), all of which are produced in the Midsund plant. The firm sells its products to various segments of the human nutrition market, such as sports nutrition, supplements, and health foods, as well as to the market within nutrition for the pet and feed industry. Geographically, the company generates maximum revenue from Europe, followed by North America and Asia.
51GF Score
Get the complete analysis for HOFBF
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOFBF has been successfully added to your 
